Login to Your Account


LONDON – The U.K. is expanding the scope of its biosimilars adoption program as experience of using them grows, more products come onto the market and use begins to expand beyond hospital settings and into primary care.

LONDON – It's so far, so good for adaptive pathways, with the EMA's final report on its pilot scheme concluding that staggered approval from a small patient subgroup to an increasingly wide patient population can support development in indications where it is hard to generate sufficient data.

MANCHESTER, U.K. – Biomedical science is facing a "reproducibility crisis" in which time, money and effort is being wasted pursuing flawed research, with patients' access to new drugs delayed as a result.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: